Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have B-ALL (or B lymphoblastic lymphoma) or DLBCL/high-grade B-cell lymphoma that has relapsed or is refractory (not improving within 6 months of last treatment)
- Have enough cancer evidence to test for both steps: at leukapheresis you must have CD19-positive cancer, and right before CAR T you must still have measurable “residual” cancer
- Have at least one measurable lesion on PET scan (FDG-avid) for DLBCL or B-ALL criteria (your team will confirm)
- Be well enough to tolerate treatment: ECOG performance status 0–2 and adequate blood counts, kidney, liver, and lung function
- Be able to have treatment safely: no pregnancy or breastfeeding, and you must use effective contraception during treatment and for 1 year after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.